For research use only · Not for human use
KLOW
GLOW + KPV: four-peptide tissue and inflammation blend
In short
KLOW adds KPV to the GLOW blend (GHK-Cu, BPC-157, TB-500). KPV is the 3-amino-acid tail of the alpha-MSH hormone and is studied in inflammation research.
Evidence level: Mostly preclinicalThe components have been studied individually; there are no clinical studies of this blend itself.
Size
- Independently tested. Janoshik Analytical results published.
- QR verification. An authenticity code on every box.
Blend components
| Component | CAS# | Formula | Molar mass |
|---|---|---|---|
| GHK-Cu | 49557-75-7 | C14H22CuN6O4 | 401.91 g/mol |
| BPC-157 | 137525-51-0 | C62H98N16O22 | 1419.55 g/mol |
| TB-500 | 77591-33-4 | C212H350N56O78S | 4963.44 g/mol |
| KPV | 67727-97-3 | C16H30N4O4 | 342.43 g/mol |
The current batch certificate for this product is not yet published on the site. Send us your lot number and we'll share it.
Request certificateWhat is KLOW?
KLOW is a multi-peptide research blend for studying tissue remodeling, cellular migration, collagen synthesis, and anti-inflammatory signaling pathways in vitro. It builds on the GLOW three-peptide combination—GHK-Cu, BPC-157, and TB-500—by adding KPV, the C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH, to enable parallel investigation of extracellular matrix mechanisms and melanocortin-related signaling.
KLOW assembles four peptides that each entered the research literature along separate paths. GHK-Cu, a copper-binding tripeptide, was first described by Loren Pickart in the 1970s and has since been examined in vitro for associations with gene-expression and matrix-remodeling pathways. BPC-157 emerged in the early 1990s from Croatian researchers studying gastric protective fractions, while TB-500 (Thymosin Beta-4) traces to Allan Goldstein's thymosin work at the National Institutes of Health in the 1960s.
The fourth component, KPV, is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (alpha-MSH). It has been investigated in preclinical research for anti-inflammatory and melanocortin-related signaling pathways, including studies of intestinal epithelial cell models. KPV is what distinguishes KLOW from the three-peptide GLOW blend: KLOW pairs GLOW's extracellular-matrix-focused peptides with an additional tripeptide studied for distinct inflammatory-signaling mechanisms.
Combining the four peptides lets researchers examine complementary in-vitro mechanisms—matrix and collagen signaling, angiogenesis, cellular migration, and melanocortin-related inflammatory pathways—within a single lyophilized preparation. This product is intended for research use only.
How should KLOW be stored?
Research peptides are supplied lyophilized (freeze-dried) . Keep sealed vials cool, dry, and protected from light until reconstitution.
After reconstitution, refrigerate prepared solutions and use sterile technique. For general laboratory diluent and handling notes, see lyophilized peptide reconstitution .
References
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108.
- Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-2151.
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51.
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
KLOW is available for laboratory research purposes only.